Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target

Benzinga · 03/22 13:58
Wedbush analyst Robert Driscoll reiterates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and maintains $8 price target.